DMPI - デルマ―・ファ―マシュ―ティカルズ (DelMar Pharmaceuticals Inc.) デルマ―・ファ―マシュ―ティカルズ



symbol DMPI
会社名 DelMar Pharmaceuticals Inc (デルマ―・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 持株会社   医療関連(Health Care)
概要 事業概要 DelMar Pharmaceuticals Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate VAL-083 as a treatment for glioblastoma multiforme (GBM) a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent which crosses the blood-brain-barrier (BBB).   デルマ―・ファ―マシュ―ティカルズはカナダ医薬品企業。臨床段階で、がん治療薬の開発に従事する。同社の候補薬「VAL-083」は脳がんの一種である多形性神経膠芽種の治療薬として開発される。また、中国において「VAL-083」の商業的権利を持ち、慢性骨髄性白血病と肺がんに対する化学療法の開発に取り組む。本社はバンク―バ―。   DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
本社所在地 Suite 720-999 West Broadway Vancouver British Columbia 07701 CAN
代表者氏名 Robert E. Hoffman ロバートE.ホフマン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 604-629-5989
設立年月日 39965
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 19人
EBITDA EBITDA(百万ドル) -11.15012
終値(lastsale) 0.7
時価総額(marketcap) 15686337.1
時価総額 時価総額(百万ドル) 14.56588
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 15.01929
当期純利益 当期純利益(百万ドル) -11.31454
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 DelMar Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 28% to $11.3M. Higher net loss reflects Research and Development increase of 42% to $7M (expense) General and administration - gross increase of 13% to $3.7M (expense) Stock-based Compensation in R&D increase from $47K to $355K (expense).


 関連キーワード  (持株会社 米国株 デルマ―・ファ―マシュ―ティカルズ DMPI DelMar Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)